Accurate Solution for Early Assessment of Osteoporosis at the Point of Care

Omnisense 7000

Millions of people worldwide are at risk of developing osteoporosis, and millions more already suffer from it. Early assessment and ongoing monitoring are key to positive outcomes. With the Sunlight Omnisense™ 7000 Quantitative Ultrasound Bone Sonometer you can offer reliable, accurate, non-invasive and safe diagnosis and monitoring of the disease - with exceptional cost-effectiveness and ease, right at the point of care.

A compact device designed for any clinic or physician office, Omnisense 7000 provides a proven, ideal way to manage and monitor osteoporosis diagnosis and treatment for any patient.

Proven Accuracy

Omnisense 7000 is based on proprietary Sunlight Omnipath™ quantitative ultrasound technology, which has been proven - in thousands of Sunlight Omnisense installations worldwide - to deliver highly accurate and safe multi-site measurement of bone density.

Omnisense 7000 leads the Sunlight family of Omnipath-based solutions – the first, and currently only, multi-site ultrasound devices available today that enable first-line early assessment and diagnosis of osteoporosis. It offers an effective alternative to the traditional x-ray-based scans where use of DXA for diagnosis or monitoring is not possible due to cost or geographic limitations of available systems and whenever x-ray exposure should be avoided.
The Omnisense™ 7000 Advantage

- Proven safety
  - Radiation-free & non-invasive
  - Utilizes market-proven Omnipath technology
- High accuracy
  - Precise measurements – a unique multi-site measurement option
  - 4 ethnical reference databases for males, females and children
- Easy to use
  - Built-in patient data management
- Affordable
  - Low system cost; no disposables
- Advanced capabilities
  - Supports Sunlight PREMIER and Pediatric software for bone density assessment in premature babies and children aged 0-18 respectively
  - Can be connected to Tetrax and Sunlight BonAge devices for expanded applications

Omnipath™ - A Proven Osteoporosis Early Assessment and Monitoring Technology - Anywhere, Anytime, for Anyone

Sunlight's patented Omnipath axial transmission technology measures the velocity of ultrasound waves propagating along the bone’s maximal strength axis. Its “along the bone” measurement eliminates soft tissue effects, enabling more accurate results.

Multi-Site - The Right Way

Omnisense is the first – and currently only - ultrasound bone sonometer on the market that can measure at multiple skeletal sites. Multi-site testing provides a better chance of identifying individual cases of osteoporosis as well as flexibility in testing patients who cannot be tested at a particular skeletal site. Multi-site measurement also has advantages in monitoring treatment results, because different bones may respond to treatment at different rates.

An Easy-to-Understand Measurement Report

All relevant information is presented in an easy-to-understand measurement report, enabling immediate diagnoses, prescriptions and referrals as needed – within minutes. The report includes:

- Measurement results — presented in an easy-to-read colored graph
- Patient details and measurement history
- WHO-compliant T-score and Z-score results

About BeamMed

BeamMed Ltd., owner of the Sunlight™ brand, develops, manufactures and markets advanced ultrasound technology and devices for early assessment, diagnosis and monitoring of osteoporosis and for bone age assessment. With thousands of Sunlight installations around the globe and a growing product offering, BeamMed is recognized as a leading provider of bone health-related diagnosis and monitoring solutions.